December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Use of patch testing essential for faster, more effective tx
June 1st 2005Allergic contact dermatitis can be a nightmare for those with serious cases, yet many dermatologists fail to use any form of patch test with their patients — a procedure that could lead to faster, more effective and definitive treatment, according to Bryan E. Anderson, M.D., assistant professor in the department of dermatology at Penn State University College of Medicine, Hershey, Pa.
Better understanding of AD portends better treatment
June 1st 2005Vancouver, British Columbia — Atopic dermatitis (AD) is on the rise around the world and affects 10 percent to 20 percent of children. The disease may continue into adulthood and may be the first step in an "atopic marathon" that leads to asthma and allergic rhinitis.
Massage benefits children with atopic dermatitis
June 1st 2005National report — The benefits of topical therapy for atopic dermatitis can be boosted with massage, according to a study in children. Massage not only improved patients' symptoms and quality of life but also helped to relieve their parents' anxiety.
Pinpointing S. aureus as AD perpetrator
June 1st 2005Orlando, Fla. — Poorly controlled atopic dermatitis (AD) may remain elusive to treatment, particularly if its pathogenesis is not understood. While it is known that the altered barrier of atopic skin provides a portal of entry for various pathogens, it is the skin inflammation in AD that reduces the ability of patients with atopy to fight infection, according to Donald Y. M. Leung, M.D., Ph.D., head of pediatric allergy-immunology at the National Jewish Medical and Research Center in Denver.
Cortisol testing demonstrates systemic safety, efficacy for AD
June 1st 2005San Diego — The lipid enhanced, emollient cream formulation of hydrocortisone butyrate 0.1 percent (Locoid, Ferndale) effectively treats moderate to severe atopic dermatitis (AD) in children and does so with excellent systemic safety, at least when used over a period of up to four weeks, said Lawrence F. Eichenfield, M.D., at the Pediatric Dermatology for the Practitioner Meeting here.
Duo offers efficient, effective photon delivery
June 1st 2005Lake Buena Vista, Fla. — Photo-Pneumatic Technology Therapy? (PPx), manufactured by Aesthera Corp., is showing promise as an innovative new approach for enhancing the safety and efficacy of hair removal and nonablative skin rejuvenation procedures, according to Vic A. Narurkar, M.D, who spoke at the Annual Meeting of the American Society for Laser Medicine and Surgery.
Add some acupuncture to your practice
June 1st 2005National report — When traditional approaches fail, many skin conditions may benefit from the addition of a few needles — acupuncture needles, that is. Some physicians are having good success integrating acupuncture into their dermatological practices.
Vitamin D deficiency unlikely, study says
June 1st 2005National report — Results of a study assessing sunlight exposure during winter months in various geographic locations across the United States refute the idea that "safe sun" photoprotection practices are associated with a risk of vitamin D deficiency, says J. Frank Nash, Ph.D., principle scientist, Procter & Gamble Co., Cincinnati.
Medicare woes add to practice difficulties
June 1st 2005Should the cuts take place as planned, 18 percent of physicians surveyed by the American Medical Association say they would stop accepting new Medicare patients; 57 percent would decrease time spent with patients; and 46 percent would reduce staffing levels.
Pilot trial: NB-UVB not enhanced by tacrolimus
May 1st 2005New Orleans — Concomitant topical treatment with tacrolimus 0.1 percent ointment (Protopic, Fujisawa) does not improve the response of generalized vitiligo to narrowband UVB phototherapy, according to the results of a randomized, double-blind, placebo-controlled, pilot study undertaken by researchers at the University of Texas Southwestern Medical Center.
Tacrolimus, UVB therapy synergistic duo
May 1st 2005Nice, France — Results of a comparative, prospective, randomized study undertaken by French dermatologists indicate that topical tacrolimus ointment 0.1 percent (Protopic, Fujisawa) plus phototherapy with a 308-nm excimer laser can be a highly effective combination for the treatment of recalcitrant, localized vitiligo.
West Nile virus skin symptoms documented
May 1st 2005New Orleans — Scientific literature rarely portrays cutaneous manifestations of West Nile virus (WNV) because these manifestations are, by nature, transient. However, a recent case report contains what is only the second publication of these symptoms.